Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Organoid models of high grade serous ovarian cancer: investigating the effect of homologous recombination mutations on genomic stability
EF 2019-20
Résumé
"High-grade serous ovarian cancer (HGS) is the most common and lethal form of ovarian cancer, with 120,000 people a year dying worldwide from this disease. Recently, new cancer-killing drugs called poly ADP ribose polymerase (PARP) inhibitors have shown promise in treating HGS. However, not all patients respond equivalently, and HGS mortality rates have seen little improvement in recent years. This underlines the urgent need for biomarkers to predict which patients may benefit from this novel therapy. A large spectrum of mutations affecting proteins involved in DNA damage repair has been identified in HGS. These mutations compromise tumour cells' ability to repair mutated DNA, forcing them to rely on a less reliable mechanism for DNA repair. PARP inhibitors exploit this vulnerability to selectively kill tumour cells. However, which DNA damage repair gene mutations confer PARP sensitivity is largely unknown. My proposed project will use organoids, which model the three-dimensional architecture of organs, to test the effects of different DNA repair mutations on non-cancerous cells. Using gene-editing technology I will mutate DNA repair genes in organoids, monitor the organoids for changes in their ability to repair DNA, and test whether the mutations confer sensitivity to PARP inhibition. Success with my project will identify biomarkers that may distinguish patients more likely to benefit from PARP inhibitor therapy. In addition, my research will develop a novel model system to improve understanding of the biology of tumours with DNA damage repair defects. I expect these findings may have the potential to provide a rationale for clinical trials that could expand the numbers of patients that receive PARP inhibitor therapy."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
428817
Name
Gibbard Evan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Organoid models of high grade serous ovarian cancer: investigating the effect of homologous recombination mutations on genomic stability
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Genetics; Gynecologic; Lentivirus; Modeling; Organoids; Ovarian
Abstract
"High-grade serous ovarian cancer (HGS) is the most common and lethal form of ovarian cancer, with 120,000 people a year dying worldwide from this disease. Recently, new cancer-killing drugs called poly ADP ribose polymerase (PARP) inhibitors have shown promise in treating HGS. However, not all patients respond equivalently, and HGS mortality rates have seen little improvement in recent years. This underlines the urgent need for biomarkers to predict which patients may benefit from this novel therapy. A large spectrum of mutations affecting proteins involved in DNA damage repair has been identified in HGS. These mutations compromise tumour cells' ability to repair mutated DNA, forcing them to rely on a less reliable mechanism for DNA repair. PARP inhibitors exploit this vulnerability to selectively kill tumour cells. However, which DNA damage repair gene mutations confer PARP sensitivity is largely unknown. My proposed project will use organoids, which model the three-dimensional architecture of organs, to test the effects of different DNA repair mutations on non-cancerous cells. Using gene-editing technology I will mutate DNA repair genes in organoids, monitor the organoids for changes in their ability to repair DNA, and test whether the mutations confer sensitivity to PARP inhibition. Success with my project will identify biomarkers that may distinguish patients more likely to benefit from PARP inhibitor therapy. In addition, my research will develop a novel model system to improve understanding of the biology of tumours with DNA damage repair defects. I expect these findings may have the potential to provide a rationale for clinical trials that could expand the numbers of patients that receive PARP inhibitor therapy."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gibbard, Evan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~